Grants for Those Living With Medical Conditions

Do you want to go to trade school? College? Do you want to pursue writing painting, sculpturing… There are a number of grants available for those with medical conditions and limited funds. Of course, you will need to submit a written statement from your doctor. I’ll provide you with some links, however, there are thousands. Grants for travel expenses. Grants for supplies. Grants for starting a program in your community. You name it! Type medical condition and interests in your search engine. Don’t forget to research medical supply companies, pharmaceutical companies, foods….


This site also services people living w/HIV/AIDS, ADHD, Cancer, MS…










Info and links for Help Pay for Insulin (Novo Nordisk)

Diabetes Care

The Diabetes PAP provides free medicine to those who qualify. If approved, a free 120-day supply of medicine will be sent to the prescribing health care providers’ office to be picked up at the patient’s convenience. Novo Nordisk will automatically contact the health care provider prior to your next refill to approve the medication reorder.

If you are a patient in need of assistance, or you know someone in need of assistance, follow these 3 simple steps to see if you qualify for free diabetes medication from Novo Nordisk:

Fill out the Patient section of the application
Gather proof of income
Take application and proof of income to your doctor to complete the Health Care Practitioner section. PLEASE DO NOT INCLUDE MEDICAL RECORDS WITH THIS APPLICATION.
How to get started: Download the US Application (English PDF) (Spanish PDF) or View Products Covered by PAP (PDF).

Patients and caregivers can also obtain more information and access to the program by calling the Novo Nordisk Patient Assistance Program toll free at 866-310-7549.

If you are a health care professional and you want additional information about the Novo Nordisk Patient Assistance Program, have eligible patients who are not yet enrolled, or have patients who are enrolled and want additional information about their eligibility, please visit the “Patient Support” section on the Physician Portal at

It’s Not A Pancreas, However, I Appreciate The Upgrade



Last month I received my new insulin pump (630G), meter, and CGM. And I had a panic attack. The packaging and booklets were overwhelming. And yes, I cried. After Tuesday’s class, I felt better. Life is always better when the instructor (who has diabetes too) simplifies three books into 2 hours. This is my 7th insulin pump since 1990. New and improved. It’s waterproof! The screen is colorful and bold! I can set the rate that I want the insulin to enter into my body! Buttons lock to avoid accidents! Did I mention the pie chart? Glucose meter needs no batteries! The list is endless. But it’s not a pancreas. And I can think of other things to buy on my wish list, besides a pump and pump gadgets.


Digestive Issues With Diabetes

If you suffer from digestive disorders

  1. See an ENT.
  2. See a nutritionist for meal planning. I eat 6 small meals as opposed to 3 meals.
  3. Cut food in small pieces and eat slowly.
  4. Avoid acidity foods.
  5. Use 2-3 pillows to prop head during sleep.

by Travis Manni ( | February 11th 2016

The longer a person lives with diabetes, the higher their risk of digestive issues. For a long time, it was unclear why, but an international study has found a possible culprit. Study researchers believe they have found that the liver of a person with Type 1 may produce an excessive amount of a protein that can hamper digestion, according to a Science Daily report.

By comparing the intestinal tissue of people with and without diabetes, researchers realized that the cells lining the intestinal tract of people with diabetes were damaged by a substance called insulin-like growth factor binding protein 3 (IGFBP3). Excess IGFBP3 can cause gastrointestinal issues like irritable bowel syndrome, delayed bowel movements, bloating, and lack of bowel control; collectively, these problems are known as diabetic enteropathy. IGFBP3 cells attach themselves to colonic stem cells, which are coincidentally responsible for repairing wounds in the intestinal lining. As these stem cells are damaged, they lose the ability to make necessary repairs, thus creating a deteriorating digestive tract over time.

Once researchers understood the cause of diabetic enteropathy, they were able to reverse colon damage in mice with diabetes by using a drug to block the circulation of IGFBP3 cells. The researchers, who didn’t name the drug used to reverse the colon damage, believe this treatment could be cultivated to treat previously untreatable digestive problems in humans.

Of course, as people with diabetes well know, a mouse “cure” doesn’t always translate into a new treatment for humans. Still, a better understanding of the culprit behind intestinal problems in people with diabetes will likely improve treatment options in the future.

Unsolicited Advice From A Friend

When a person continuously e-mails you cures for diabetes without understanding the many forms of the disease, what do you do? I click the setting key and type their e-mail address in the filter box. When they use the following words: diabetes, tea, herbs, cleansing, and juicing. Her propaganda is deleted. When asks if I received the message I answer, “No. The trash received it.”

Class Action Suit Against Novo Nordisk (Insulin Nation)

The Class-Action Lawsuit Against Novo Nordisk
It’s alleged that price fixing to keep the price of insulin high may have obscured trouble with the company’s bottom line.


editor | January 23rd 2017

Have you ever fantasized about suing drugmakers who jack up the price of insulin? Novo Nordisk is being sued for its drug pricing, but not by its customers.


A class action lawsuit has been filed against Novo Nordisk by a group of investors who say they were misled about earnings forecasts. It’s alleged the drugmaker hid market trouble by colluding with other drug companies to keep the price of insulin artificially high. The lawsuit was filed by Bernstein Litowitz Berger & Grossmann LLP on behalf of the Lehigh County (PA) Employees’ Retirement System, but it can include anyone who invested in Novo Nordisk between April 30, 2015, to October 27, 2016.

(As much as it may seem like buying a vial of Novo insulin is expensive enough for one to be considered an investor in the company, the lawsuit does not include customers.)

The suit seems to stem from an overly optimistic earnings forecast in early 2016 that projected long-term growth of 10 percent, according to a Law360 report. That projection was fueled by triple-digit growth for its new basal insulin, Tresiba, according to a Motley Fool report. Novo’s plan was for Tresiba to become the Lantus-killer in the basal insulin market, but that dream was derailed with Eli Lilly’s December release of Basaglar, a biosimilar (read “generic”) version of Lantus. With Basaglar on the horizon and increasing public unease over high drug prices, pharmacy benefits managers have been able to negotiate steep discounts with insulin makers or exclude some expensive brands altogether. This has cut into sales of Tresiba and Victoza, a GLP-1 drug.

Novo stock, which had been trading at more than $53 a share a year ago stands at $35.73 as of January 17, 2017. In 2016, Novo’s CEO stepped down, and the company announced plans to cut 1,000 jobs.

The 2016 presidential election also brought a high level of uncertainty to the business plans of insulin makers. In October, two prominent lawmakers asked the Justice Department to investigate insulin price fixing. Pharma companies bracing for increased regulation under Hillary Clinton rallied when Donald Trump surprised nearly everyone by winning the electoral college vote. That rally proved fragile, however, as Trump has periodically made overtures about curbing drug prices. Most recently, during a wide-ranging press January 11 press conference, Trump said drug companies were “getting away with murder.” That was enough to send drug company stock value tumbling, according to a CNN Money report.

So far there has been no word of copycat class action lawsuits from investors with the other insulin-making companies.

Glucagon Recall from Nordisk


Novo Nordisk has announced that it is recalling some batches of its GlucaGen HypoKit after two users complained that the needles detached during use. Novo Nordisk’s investigators found that a small number of needles do indeed detach, according to a MPR report.

In total, just over 70,000 needles are being recalled from the following four batches:

Batch: FS6X270, Expiry: 09/30/2017
Batch: FS6X296, Expiry: 09/30/2017
Batch: FS6X538, Expiry: 09/30/2017
Batch: FS6X597, Expiry: 09/30/2017
Batch: FS6X797, Expiry: 09/30/2017
Batch: FS6X875, Expiry: 09/30/2017


All six batches were manufactured after February 15, 2016. Lilly also makes a glucagon emergency kit; this recall does not affect that product.

Perhaps this latest recall will hasten the development of easier-to-use glucagon products. Companies have been working on room-temperature-stable glucagon and a glucagon patch. Also, Lilly has acquired the rights to a formulation of glucagon that can be taken nasally.